Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Damage Response and Gene Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FANCA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FANCA Recombinant Protein High purity (>90%), Endotoxin Controlled. Sequence Verified. Theoretical MW ~163 kDa. Suitable for protein-protein interaction studies. |
View FANCA Products |
| Gene Delivery | FANCA Promise-ORF / Lentivirus Full-length human FANCA ORF for expression, stable cell line generation, and functional rescue assays. |
View FANCA Products |
| Benchmark Ab | Anti-FANCA Recombinant Antibody Recombinant positive control for Western Blot, Immunoprecipitation, and intracellular localization assays. |
View FANCA Products |
| Validator | FANCA siRNA Set For target knockdown verification to confirm assay specificity and simulate target inhibition. |
View FANCA Products |
| Related Target A | FANCD2 Downstream effector of the Fanconi Anemia core complex. FANCD2 monoubiquitination serves as the primary functional readout for FANCA activity. |
View FANCD2 Products |
| Related Target B | PARP1 Key DNA damage repair enzyme. Inhibiting FANCA induces synthetic lethality when combined with PARP1 inhibitors in homologous recombination-proficient tumors. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Expression of large, multi-domain intracellular protein (~163 kDa) | Insect cell/mammalian expression systems optimized for eukaryotic folding, sequence-verified to ensure structural integrity. |
| Functional rescue validation in gene therapy development | High-titer, sequence-verified Lentiviral vectors carrying full-length human FANCA ORF for robust transduction. |
| Lack of reliable positive controls for intracellular assays | High-affinity clinical-grade recombinant antibodies for specific target detection. |
| False positives in small molecule screening | Sequence-specific siRNA pools provided for target-specific knockdown control. |
Live FANCA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for FANCA is bifurcated into two distinct R&D frontiers. In regenerative medicine and rare diseases, gene therapy is leading the charge, aimed at restoring wild-type FANCA function in Fanconi Anemia patients. Conversely, in oncology, drug discovery focuses on inhibiting FANCA or the wider Fanconi Anemia (FA) core complex to sensitize cancer cells to DNA-damaging chemotherapies (such as cisplatin) and PARP inhibitors, exploiting synthetic lethality in homologous recombination-proficient (HRP) tumors.
"The race for FANCA therapeutics is intensifying, with major players shifting focus from traditional gene addition to highly targeted small molecule inhibitors and precise gene editing. As first-generation therapies reach the clinic, the next wave of R&D is targeting critical protein-protein interactions within the FA core complex."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (LVR) | Rocket Pharmaceuticals | Fanconi Anemia Type A | Functional Rescue Assay (Need high-titer Lentivirus & sequence-verified ORF) |
| Small Molecule Inhibitors | Biotech / Academic Consortia | Chemoresistant Solid Tumors | Protein-Protein Interaction Assay (Need high-purity recombinant FANCA core complex proteins) |
| Gene Editing (CRISPR) | Editas Medicine, Beam Therapeutics | Fanconi Anemia Type A | Knockout Validation & Off-target profiling (Need sequence-verified siRNA and control antibodies) |